Estimaciones de analistas de Wall Street para Emergent BioSolutions Inc. (EBS): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-04 | $-0.37 | ||
| 2026-08-05 | $0.60 | $-0.09 | +805.9% |
| 2026-04-30 | $0.21 | $-0.25 | +184.0% |
| 2026-02-26 | $-0.43 | $0.11 | -490.9% |
| 2025-10-29 | $1.06 | $-0.12 | +983.3% |
| 2025-08-06 | $0.16 | $-0.26 | +161.5% |
| 2025-05-07 | $0.71 | $0.49 | +44.9% |
| 2025-03-03 | $0.05 | $-0.35 | +114.3% |
Ratios de valoración
| Precio / Valor contable | 0.99 |
| EV / EBITDA | -31.72 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $488.8M | $560.9M | $782.4M | $1.11B | $1.58B | $1.77B | $1.12B | $1.05B | $1.04B | $742.9M |
| Coste de Ventas | $244.0M | $277.3M | $462.0M | $622.9M | $714.2M | $980.4M | $644.5M | $689.3M | $668.2M | $392.3M |
| Beneficio Bruto | $244.8M | $283.6M | $320.4M | $483.1M | $863.1M | $793.2M | $473.0M | $360.0M | $375.4M | $350.6M |
| I+D | $106.9M | $97.4M | $142.8M | $226.2M | $237.9M | $235.2M | $188.3M | $111.4M | $70.7M | $53.8M |
| Generales y Administrativos | $143.1M | $142.9M | $202.5M | $273.5M | $304.1M | $348.7M | $339.5M | $356.7M | $298.7M | $186.6M |
| Gastos Operativos | $139.3M | $159.3M | $230.6M | $369.0M | $424.6M | $451.8M | $643.0M | $1.09B | $484.1M | $240.4M |
| Beneficio Operativo | $105.5M | $124.3M | $89.8M | $114.1M | $438.5M | $341.4M | -$170.0M | -$726.4M | -$108.7M | $110.2M |
| EBITDA | $132.9M | $174.7M | $155.1M | $258.9M | $609.2M | $504.2M | $15.7M | -$47.0M | $53.4M | $240.4M |
| Gastos por Intereses | $7.6M | $6.6M | $9.9M | $38.4M | $31.3M | $34.5M | $37.3M | $87.9M | $71.0M | $59.3M |
| Beneficio Antes de Impuestos | $99.2M | $118.6M | $81.5M | $77.4M | $411.9M | $303.2M | -$219.0M | -$731.2M | -$142.9M | $82.8M |
| Impuestos | $36.7M | $36.0M | $18.8M | $22.9M | $106.1M | $83.7M | -$7.4M | $29.3M | $47.7M | $30.2M |
| Beneficio Neto | $51.8M | $82.6M | $62.7M | $54.5M | $305.8M | $219.5M | -$211.6M | -$760.5M | -$190.6M | $52.6M |
| BPA | $1.29 | $1.98 | $1.25 | $1.06 | $5.79 | $4.10 | $-4.22 | $-14.85 | $-3.60 | $0.98 |
| BPA Diluido | $1.13 | $1.71 | $1.22 | $1.04 | $5.67 | $4.06 | $-4.22 | $-14.85 | $-3.60 | $0.93 |
| Acciones en Circulación (Diluidas) | $49.3M | $50.3M | $51.4M | $52.4M | $53.8M | $54.1M | $50.1M | $51.2M | $53.0M | $56.7M |
Precio
| Precio | $6.75 |
| Capitalización | $348M |
| Bolsa | NYSE |
| País | US |
Empresas relacionadas: AQST · CMPS · CRVS · ESPR · OLMA · ORGO · PRTA
Explorar sector: Healthcare · Drug Manufacturers - Specialty & Generic
Más secciones de EBS: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones